Back to top
more

Arcutis Biotherapeutics (ARQT)

(Delayed Data from NSDQ)

$10.62 USD

10.62
2,052,961

-0.11 (-1.03%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $10.60 -0.02 (-0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New Strong Buy Stocks for January 11th

by Zacks Equity Research

ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.

The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics

by Zacks Equity Research

Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog.

Sundeep Ganoria headshot

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

by Sundeep Ganoria

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

by Zacks Equity Research

The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.

After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT)

by Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -50.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Arcutis Biotherapeutics, Inc. (ARQT)

by Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Arcutis Biotherapeutics, Inc. (ARQT) Loses -51.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Arcutis Biotherapeutics, Inc. (ARQT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion

by Zacks Equity Research

Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.

Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock Up

by Zacks Equity Research

Arcutis (ARQT) submits sNDA, seeking label expansion of Zoryve (roflumilast) cream 0.15% to treat patients with atopic dermatitis.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of 4.92% and 6.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -0.77% and 20.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study

by Zacks Equity Research

Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

Wall Street Analysts Believe Arcutis Biotherapeutics, Inc. (ARQT) Could Rally 134%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Arcutis Biotherapeutics, Inc. (ARQT) points to a 134.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Albireo Pharma (ALBO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Can Arcutis Biotherapeutics, Inc. (ARQT) Climb 123% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Arcutis Biotherapeutics, Inc. (ARQT) points to a 122.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

All You Need to Know About Arcutis Biotherapeutics, Inc. (ARQT) Rating Upgrade to Buy

by Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe

by Zacks Equity Research

Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.

Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval

by Zacks Equity Research

Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.

Arcutis (ARQT) Terminates Study of Drug to Treat Vitiligo

by Zacks Equity Research

Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.

Arcutis Biotherapeutics, Inc. (ARQT) Upgraded to Buy: Here's Why

by Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.